Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

Kyra J. Fuchs, Marian van de Meent, M. Willy Honders, Indu Khatri, Michel G. D. Kester, Eva A. S. Koster, Georgia Koutsoumpli, Arnoud H. de Ru, Cornelis A. M. van Bergen, Peter A. van Veelen, Peter A. C. ’t Hoen, Peter van Balen, Erik B. van den Akker, J. Hendrik Veelken, Constantijn J. M. Halkes, J. H. Frederik Falkenburg, Marieke Griffioen

Blood (2024) 143 (18): 1856–1872.

https://doi.org/10.1182/blood.2023022343

Published: 2024

Includes: Supplemental data

Journal Articles

T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L.A. Wachsmann, Renate S. Hagedoorn, Dennis F.G. Remst, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2022) 140 (Supplement 1): 10292–10293.

https://doi.org/10.1182/blood-2022-170314

Published: 2022

Journal Articles

Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain

Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L.A. Wachsmann, Renate S. Hagedoorn, Michel G.D. Kester, Dennis F.G. Remst, Dirk M. van der Steen, Arnoud H. de Ru, Els P. van Hees, Marieke Griffioen, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2022) 140 (Supplement 1): 4498–4499.

https://doi.org/10.1182/blood-2022-156923

Published: 2022

Journal Articles

Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation

Nadine E. Struckman, Sebastian Klobuch, Michel G.D. Kester, Wendy de Klerk, Arnoud H. de Ru, Mirjam H.M. Heemskerk, Peter A. van Veelen, Peter van Balen, J.H.Frederik Falkenburg, Marieke Griffioen

Blood (2022) 140 (Supplement 1): 4545–4546.

https://doi.org/10.1182/blood-2022-166282

Published: 2022

Journal Articles

Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia

Dyantha I. Van Der Lee, BSc., Helena M. Bijen, MSc, Renate S. Hagedoorn, ing., Willy M. Honders, ing., Michel G.D. Kester, ing., Dirk M. van der Steen, ing., Arnoud H. de Ru, ing., Inge Jedema, PhD, Hendrik Veelken, MD PhD, Mirjam H.M. Heemskerk, PhD, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Marieke Griffioen, PhD

Blood (2017) 130 (Supplement 1): 168.

https://doi.org/10.1182/blood.V130.Suppl_1.168.168

Published: 2017

Journal Articles

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1

Lorenz Jahn, Pleun Hombrink, Renate S. Hagedoorn, Michel G. D. Kester, Dirk M. van der Steen, Tania Rodriguez, Tsvetelina Pentcheva-Hoang, Arnoud H. de Ru, Marjolein P. Schoonakker, Miranda H. Meeuwsen, Marieke Griffioen, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk

Blood (2017) 129 (10): 1284–1295.

https://doi.org/10.1182/blood-2016-09-737536

Published: 2017

Includes: Supplemental data

Journal Articles

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation

Mir Farshid Alemdehy, Jurgen R. Haanstra, Hans W. J. de Looper, Paulina M. H. van Strien, Judith Verhagen-Oldenampsen, Yvette Caljouw, Mathijs A. Sanders, Remco Hoogenboezem, Arnoud H. de Ru, George M. C. Janssen, Stephanie E. Smetsers, Marc B. Bierings, Peter A. van Veelen, Marieke von Lindern, Ivo P. Touw, Stefan J. Erkeland

Blood (2015) 125 (25): 3937–3948.

https://doi.org/10.1182/blood-2014-11-612507

Published: 2015

Includes: Supplemental data

Journal Articles

Allo-HLA–reactive T cells inducing graft-versus-host disease are single peptide specific

Avital L. Amir, Dirk M. van der Steen, Renate S. Hagedoorn, Michel G. D. Kester, Cornelis A. M. van Bergen, Jan W. Drijfhout, Arnoud H. de Ru, J. H. Frederik Falkenburg, Peter A. van Veelen, Mirjam H. M. Heemskerk

Blood (2011) 118 (26): 6733–6742.

https://doi.org/10.1182/blood-2011-05-354787

Published: 2011

Journal Articles

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice

Annemarie Meenhuis, Peter A. van Veelen, Hans de Looper, Nicole van Boxtel, Iris J. van den Berge, Su M. Sun, Erdogan Taskesen, Patrick Stern, Arnoud H. de Ru, Arjan J. van Adrichem, Jeroen Demmers, Mojca Jongen-Lavrencic, Bob Löwenberg, Ivo P. Touw, Phillip A. Sharp, Stefan J. Erkeland

Blood (2011) 118 (4): 916–925.

https://doi.org/10.1182/blood-2011-02-336487

Published: 2011

Includes: Supplemental data

Journal Articles

Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation

Maarten L. Zandvliet, J.H. Frederik Falkenburg, Michel G.D. Kester, Arnoud H. de Ru, Peter A. van Veelen, Roelof Willemze, Henk-Jan Guchelaar, Pauline Meij

Blood (2008) 112 (11): 3904.

https://doi.org/10.1182/blood.V112.11.3904.3904

Published: 2008

Journal Articles

Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

Cornelis A. M. van Bergen, Michel G. D. Kester, Inge Jedema, Mirjam H. M. Heemskerk, Simone A. P. van Luxemburg-Heijs, Freke M. Kloosterboer, W. A. Erik Marijt, Arnoud H. de Ru, M. Ron Schaafsma, Roel Willemze, Peter A. van Veelen, J. H. Frederik Falkenburg

Blood (2007) 109 (9): 4089–4096.

https://doi.org/10.1182/blood-2006-08-043935

Published: 2007

Journal Articles

ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells.

Cornelis A. Van Bergen, Michel G. Kester, Inge Jedema, Mirjam H. Heemskerk, Simone A. Van Luxemburg, Freke M. Kloosterboer, Erik W. Marijt, Arnoud H. De Ru, Martyn R. Schaafsma, Roelof Willemze, Peter A. Van Veelen, J.H. Frederik Falkenburg

Blood (2006) 108 (11): 549.

https://doi.org/10.1182/blood.V108.11.549.549

Published: 2006

NARROW

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain

Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation

Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation

Allo-HLA–reactive T cells inducing graft-versus-host disease are single peptide specific

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice

Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation

Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only